Please login to the form below

Medivation

This page shows the latest Medivation news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Talzenna cleared for breast cancer in Europe

Talzenna was acquired by Pfizer as part of its $14bn takeover of Medivation in 2016, and earlier this month the company made another mid-range acquisition in cancer, agreeing to buy

Latest news

Pfizer adds Array to cancer arsenal with $11bn acquisition

The acquisition announced yesterday is the big pharma company's largest since it bought another oncology specialist, Medivation in 2016 for $14bn, and could help build a third cancer blockbuster franchise ... The 2016 Medivation buyout saw its value drop
Hudson named Brandicourt’s successor as Sanofi’s CEO

rivals when trying to bolt on Medivation (which went to Pfizer) and Actelion (bought by Johnson &Johnson).
Pfizer names next CEO as Read retires

One M&A deal that did go through was the $14bn acquisition of Medivation in 2016, though many analysts say the big pharma company overpaid for the firm and its oncology
Daily Brief: Keytruda and microbiome synergy, Pfizer's files PARP contender and more

The company acquired the candidate when it bought out Medivation for $14bn in 2016, and needs to recoup its investment with a successful PARP competitor.
Sanofi sells European generics to Advent for $2.4bn

for Medivation and Actelion.

More from news
Approximately 15 fully matching, plus 37 partially matching documents found.

Latest Intelligence

Deal Watch December 2016

Only August 2016 ($21.4bn, including $14bn for the Pfizer Medivation deal) came close. ... Excluding the Shire-Baxalta and Pfizer-Medivation deals, the figure for total (disclosed) upfront payments typically ranges between $1-6bn per month.
Deal Watch August 2016

So the conclusion is that Pfizer is mainly expecting to generate value from Medivation's late stage oncology programme. ... Sanofi sought to take control of Medivation's board using a paper vote.
Deal Watch May 2016

on. Following its rejection of the $9.3bn [$52.5 per share in cash, 36% premium] on the table from Sanofi, Medivation is now open to bids, encouraging competition. ... In the light of this, Sanofi has elected to go hostile and has filed with the SEC
Deal Watch April 2016

Sanofi would like to merge with Medivation as it makes “strong strategic sense”. ... Unfortunately the Medivation CEO, David Hung, was not interested in a meeting or even hearing Sanofi's proposal.
Pharma deals in August 2015

Licence. 700. BioMarin. Medivation. Talazoparib a PARP inhibitor in P3 for BRCA mutated breast cancer.

More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest appointments

Revolution Medicines appoints Dr Stephen Kelsey

Prior to his time at Onkaido Therapeutics, Kelsey has served in several senior positions at Medivation, Generon and Genentech, where he held the role of vice president, haematology and oncology.
Avanir Pharmaceuticals appoints new president and CEO

He has over 20 years of drug development and commercialisation experience, having previously worked as chief commercial officer for Medivation and in various senior management roles at Johnson &Johnson and Centocor.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Strategic Planner, Healthcare Advertising Agency: Salary TBC

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director – UK Office: Excellent salary and benefits

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Director, Healthcare Communications: Salary TBC

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Subscribe to our email news alerts

PMHub

Add my company

Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Empowered patients: shaking the foundations of healthcare: Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service: The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence: Data is the most valued commodity of the modern world. For P&P it's all about the application....